Cargando…

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes

Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is often assessed with serial mixed-meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead use β-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Gitelman, Stephen E., Evans-Molina, Carmella, Guolo, Annamaria, Mari, Andrea, Ferrannini, Ele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450822/
https://www.ncbi.nlm.nih.gov/pubmed/37368990
http://dx.doi.org/10.2337/db23-0196
_version_ 1785095283779043328
author Gitelman, Stephen E.
Evans-Molina, Carmella
Guolo, Annamaria
Mari, Andrea
Ferrannini, Ele
author_facet Gitelman, Stephen E.
Evans-Molina, Carmella
Guolo, Annamaria
Mari, Andrea
Ferrannini, Ele
author_sort Gitelman, Stephen E.
collection PubMed
description Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is often assessed with serial mixed-meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead use β-cell glucose sensitivity (βGS) to assess changes in β-cell function, incorporating insulin secretion for a given serum glucose into the assessment of β-cell function. We evaluated changes in βGS in individuals enrolled in the placebo arm of 10 T1D trials performed at diabetes onset. We found that βGS showed a more rapid decline in children, as compared with adolescents and adults. Individuals in the top quartile of βGS baseline distribution had a slower rate in loss of glycemic control time over time. Notably, half of this group were children and adolescents. Finally, to identify predictors of glycemic control throughout follow-up, we ran multivariate Cox models and found that incorporating βGS significantly improved the overall model. Taken together, these data suggest that βGS may be of great utility in predicting those more likely to have a more robust clinical remission and may be of use in design of new-onset diabetes clinical trials and in evaluating response to therapies. ARTICLE HIGHLIGHTS: We undertook this study to better predict β-cell loss following type 1 diabetes diagnosis. We set out to answer whether β-cell glucose sensitivity (βGS) improves means to evaluate β-cell function postdiagnosis and whether βGS correlates with clinical outcomes. We found that βGS declines faster in children, subjects in the top baseline quartile of βGS exhibit slower β-cell decline (half are children), and incorporating βGS into multivariate Cox models for glycemic improves the model. The implications of our findings are that βGS predicts those likely to have robust clinical remissions and may help with clinical trials design.
format Online
Article
Text
id pubmed-10450822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-104508222023-08-26 β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes Gitelman, Stephen E. Evans-Molina, Carmella Guolo, Annamaria Mari, Andrea Ferrannini, Ele Diabetes Islet Studies Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is often assessed with serial mixed-meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead use β-cell glucose sensitivity (βGS) to assess changes in β-cell function, incorporating insulin secretion for a given serum glucose into the assessment of β-cell function. We evaluated changes in βGS in individuals enrolled in the placebo arm of 10 T1D trials performed at diabetes onset. We found that βGS showed a more rapid decline in children, as compared with adolescents and adults. Individuals in the top quartile of βGS baseline distribution had a slower rate in loss of glycemic control time over time. Notably, half of this group were children and adolescents. Finally, to identify predictors of glycemic control throughout follow-up, we ran multivariate Cox models and found that incorporating βGS significantly improved the overall model. Taken together, these data suggest that βGS may be of great utility in predicting those more likely to have a more robust clinical remission and may be of use in design of new-onset diabetes clinical trials and in evaluating response to therapies. ARTICLE HIGHLIGHTS: We undertook this study to better predict β-cell loss following type 1 diabetes diagnosis. We set out to answer whether β-cell glucose sensitivity (βGS) improves means to evaluate β-cell function postdiagnosis and whether βGS correlates with clinical outcomes. We found that βGS declines faster in children, subjects in the top baseline quartile of βGS exhibit slower β-cell decline (half are children), and incorporating βGS into multivariate Cox models for glycemic improves the model. The implications of our findings are that βGS predicts those likely to have robust clinical remissions and may help with clinical trials design. American Diabetes Association 2023-09 2023-06-27 /pmc/articles/PMC10450822/ /pubmed/37368990 http://dx.doi.org/10.2337/db23-0196 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Islet Studies
Gitelman, Stephen E.
Evans-Molina, Carmella
Guolo, Annamaria
Mari, Andrea
Ferrannini, Ele
β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title_full β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title_fullStr β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title_full_unstemmed β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title_short β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes
title_sort β-cell glucose sensitivity to assess changes in β-cell function in recent-onset stage 3 type 1 diabetes
topic Islet Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450822/
https://www.ncbi.nlm.nih.gov/pubmed/37368990
http://dx.doi.org/10.2337/db23-0196
work_keys_str_mv AT gitelmanstephene bcellglucosesensitivitytoassesschangesinbcellfunctioninrecentonsetstage3type1diabetes
AT evansmolinacarmella bcellglucosesensitivitytoassesschangesinbcellfunctioninrecentonsetstage3type1diabetes
AT guoloannamaria bcellglucosesensitivitytoassesschangesinbcellfunctioninrecentonsetstage3type1diabetes
AT mariandrea bcellglucosesensitivitytoassesschangesinbcellfunctioninrecentonsetstage3type1diabetes
AT ferranniniele bcellglucosesensitivitytoassesschangesinbcellfunctioninrecentonsetstage3type1diabetes